166 related articles for article (PubMed ID: 26352795)
1. Rational design of selective small-molecule inhibitors for β-catenin/B-cell lymphoma 9 protein-protein interactions.
Hoggard LR; Zhang Y; Zhang M; Panic V; Wisniewski JA; Ji H
J Am Chem Soc; 2015 Sep; 137(38):12249-60. PubMed ID: 26352795
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Optimization of Small-Molecule Inhibitors for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Zhang M; Wang Z; Zhang Y; Guo W; Ji H
J Med Chem; 2018 Apr; 61(7):2989-3007. PubMed ID: 29566337
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 1-Benzoyl 4-Phenoxypiperidines as Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Li Z; Zhang M; Teuscher KB; Ji H
J Med Chem; 2021 Aug; 64(15):11195-11218. PubMed ID: 34270257
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors.
Sang P; Zhang M; Shi Y; Li C; Abdulkadir S; Li Q; Ji H; Cai J
Proc Natl Acad Sci U S A; 2019 May; 116(22):10757-10762. PubMed ID: 31088961
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 2-(3-(3-Carbamoylpiperidin-1-yl)phenoxy)acetic Acid Derivatives as Novel Small-Molecule Inhibitors of the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Wang Z; Zhang M; Luo W; Zhang Y; Ji H
J Med Chem; 2021 May; 64(9):5886-5904. PubMed ID: 33902288
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Side-Chain Convergence of Hydrophobic α-Helical Hot Spots To Design Small-Molecule Mimetics: Key Binding Features for
Wang Z; Ji H
J Med Chem; 2019 Nov; 62(21):9906-9917. PubMed ID: 31593458
[TBL] [Abstract][Full Text] [Related]
7. Structure-Based Design of 1,4-Dibenzoylpiperazines as β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction Inhibitors.
Wisniewski JA; Yin J; Teuscher KB; Zhang M; Ji H
ACS Med Chem Lett; 2016 May; 7(5):508-13. PubMed ID: 27190602
[TBL] [Abstract][Full Text] [Related]
8. Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling.
Takada K; Zhu D; Bird GH; Sukhdeo K; Zhao JJ; Mani M; Lemieux M; Carrasco DE; Ryan J; Horst D; Fulciniti M; Munshi NC; Xu W; Kung AL; Shivdasani RA; Walensky LD; Carrasco DR
Sci Transl Med; 2012 Aug; 4(148):148ra117. PubMed ID: 22914623
[TBL] [Abstract][Full Text] [Related]
9. Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Wang Z; Zhang M; Quereda V; Frydman SM; Ming Q; Luca VC; Duckett DR; Ji H
J Med Chem; 2021 Aug; 64(16):12109-12131. PubMed ID: 34382808
[TBL] [Abstract][Full Text] [Related]
10. A zebrafish chemical suppressor screening identifies small molecule inhibitors of the Wnt/β-catenin pathway.
Nishiya N; Oku Y; Kumagai Y; Sato Y; Yamaguchi E; Sasaki A; Shoji M; Ohnishi Y; Okamoto H; Uehara Y
Chem Biol; 2014 Apr; 21(4):530-540. PubMed ID: 24684907
[TBL] [Abstract][Full Text] [Related]
11. State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors.
Sheng C; Dong G; Miao Z; Zhang W; Wang W
Chem Soc Rev; 2015 Nov; 44(22):8238-59. PubMed ID: 26248294
[TBL] [Abstract][Full Text] [Related]
12. A Structural Perspective on the Modulation of Protein-Protein Interactions with Small Molecules.
Demirel HC; Dogan T; Tuncbag N
Curr Top Med Chem; 2018; 18(8):700-713. PubMed ID: 29852872
[TBL] [Abstract][Full Text] [Related]
13. An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.
de la Roche M; Rutherford TJ; Gupta D; Veprintsev DB; Saxty B; Freund SM; Bienz M
Nat Commun; 2012 Feb; 3():680. PubMed ID: 22353711
[TBL] [Abstract][Full Text] [Related]
14. Prospective discovery of small molecule enhancers of an E3 ligase-substrate interaction.
Simonetta KR; Taygerly J; Boyle K; Basham SE; Padovani C; Lou Y; Cummins TJ; Yung SL; von Soly SK; Kayser F; Kuriyan J; Rape M; Cardozo M; Gallop MA; Bence NF; Barsanti PA; Saha A
Nat Commun; 2019 Mar; 10(1):1402. PubMed ID: 30926793
[TBL] [Abstract][Full Text] [Related]
15. Chemical Space Overlap with Critical Protein-Protein Interface Residues in Commercial and Specialized Small-Molecule Libraries.
Si Y; Xu D; Bum-Erdene K; Ghozayel MK; Yang B; Clemons PA; Meroueh SO
ChemMedChem; 2019 Jan; 14(1):119-131. PubMed ID: 30548204
[TBL] [Abstract][Full Text] [Related]
16. New ZW4864 Derivatives as Small-Molecule Inhibitors for the β-Catenin/BCL9 Protein-Protein Interaction.
Wang Z; Zhang M; Thompson HM; Ji H
ACS Med Chem Lett; 2022 May; 13(5):865-870. PubMed ID: 35586435
[TBL] [Abstract][Full Text] [Related]
17. Probing Protein Surfaces: QSAR Analysis with Helix Mimetics.
Azzarito V; Rowell P; Barnard A; Edwards TA; Macdonald A; Warriner SL; Wilson AJ
Chembiochem; 2016 Apr; 17(8):768-73. PubMed ID: 26690307
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of quercetin derivatives as novel β-catenin/B-cell lymphoma 9 protein-protein interaction inhibitors.
Shen LA; Peng X; Bao Y; Liu C; Zhang H; Li J; Zhu D; Zhang Q
Eur J Med Chem; 2023 Feb; 247():115075. PubMed ID: 36599228
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Novel 3-Phenylpiperidine Derivatives Targeting the β-Catenin/B-Cell Lymphoma 9 Interaction as a Single Agent and in Combination with the Anti-PD-1 Antibody for the Treatment of Colorectal Cancer.
Zhang H; Liu C; Chen Q; Shen LA; Xiao W; Li J; Wang Y; Zhu D; Zhang Q; Li J
J Med Chem; 2023 Jan; 66(2):1349-1379. PubMed ID: 36630177
[TBL] [Abstract][Full Text] [Related]
20. Design criteria for minimalist mimics of protein-protein interface segments.
Taechalertpaisarn J; Lyu RL; Arancillo M; Lin CM; Jiang Z; Perez LM; Ioerger TR; Burgess K
Org Biomol Chem; 2019 Jan; 17(4):908-915. PubMed ID: 30629068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
